Tejas Networks completes delivery of 17,000 IP/MPLS routers for BharatNet Phase III
BENGALURU, India, March 30, 2026 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE:…
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe…
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of…
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements…
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the…
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc.…
Otelier Adds Ani Gujrathi as Chief Technology & Product Officer to Drive Next Phase of Innovation
With more than 20 years of experience scaling B2B SaaS, modernizing platforms,…
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026
March 10, 2026 08:05 ET | Source: NKGen Biotech, Inc. SANTA ANA,…
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3…
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026 14:00 ET | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British…
